Loading...
NPI 1447601695 · Covington, KY · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Gravity Diagnostics, LLC is a clinical medical laboratory provider located in Covington, Kentucky. This profile covers 48 Medicare and 153 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Gravity Diagnostics, LLC |
| Address | 812 Russell St |
| City | Covington |
| State | KY |
| ZIP | 41011 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 29, 2016 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $116.2M |
| Medicare | $1.6M |
GRAVITY DIAGNOSTICS, LLC’s billing profile is dominated by clinical toxicology services: the Medicare and Medicaid top-line codes are principally definitive drug tests (G0483, G0482, G0481, G0480) and a high-volume presumptive screen (80307). The code descriptors indicate this is primarily a laboratory that performs GC/MS- or LC/MS-based definitive testing plus instrumented presumptive drug screens, with a secondary mix that includes molecular/genetic panels (81418, 81225) and various infectious-agent assays. This combination of codes is consistent with a centralized reference lab handling both routine public-health panels and complex confirmatory toxicology work.
This provider has a highly skewed payer mix: total Medicare revenue is $1.6M while total Medicaid revenue is $116.2M, so Medicaid accounts for the overwhelming share of billed revenue. In practical terms the business operates at Medicaid scale rather than Medicare scale, making state-level Medicaid relationships the dominant commercial driver for this entity.
Revenue concentration within each payer is high. On Medicare, the precomputed top 3 Medicare codes by revenue account for 58.8% of this provider's total Medicare revenue, with G0483 ($389K, 24.9%), G0482 ($294.3K, 18.9%), and 80307 ($234.1K, 15.0%) together driving the majority of Medicare receipts and signaling heavy dependence on toxicology services for Medicare revenue.
Medicaid revenue is even more concentrated in a few toxicology services: the precomputed top 3 Medicaid codes by revenue account for 67.5% of this provider's total Medicaid revenue, led by G0481 ($35.1M, 31.8%), 80307 ($25.1M, 22.7%), and G0482 ($14.4M, 13.0%). This pattern shows the lab’s Medicaid book is highly dependent on a small set of drug-testing codes, which dominate overall revenue generation at the state level.
Competitive standing differs sharply between payers. On Medicare the provider posts above-typical national volumes for key toxicology codes (G0483 ranks #66 of 1063, 94th percentile; G0482 ranks #43 of 1618, 97th percentile) and 80307 ranks #59 of 4760 (99th percentile), indicating stronger-than-average activity for these services nationally but not a single dominant national footprint.
In its home state for Medicaid the provider is a dominant, high-volume player for multiple codes: G0481 ranks #1 of 83 providers in-state (100th percentile; extreme outlier), 80307 ranks #1 of 342 (100th percentile; extreme outlier), and G0482 ranks #1 of 48 (100th percentile; extreme outlier). Multiple additional Medicaid codes (e.g., 87798, 87522, 86481) also rank at or near #1 in-state, reinforcing that GRAVITY DIAGNOSTICS is a major statewide laboratory for both drug testing and infectious-disease panels.
The provider’s Medicaid claim volumes include very large counts for public-health and infectious testing: for example, U0004 shows 103.1K claims ($4.8M revenue), 87491 shows 56.3K claims ($1.2M revenue), 87591 shows 55.7K claims ($1.2M revenue), and 87661 shows 55.1K claims ($1.1M revenue). These high claim counts and top in-state ranks for multiplex and STI testing suggest significant throughput capacity and likely participation in state testing programs or high-volume contracting with Medicaid payers.
GRAVITY DIAGNOSTICS has an established enrollment history (NPI enumerated 2016-06-29 (~10 years ago)), which, combined with the provider’s dominant in-state Medicaid volumes and concentration in specialized toxicology and high-throughput infectious testing, suggests a mature laboratory operation with built capacity for large Medicaid contracts and centralized confirmatory testing workflows.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
48 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,610 | $240 | $389K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,510 | $200 | $294.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 3,840 | $60 | $234.1K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,330 | $150 | $203.6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,680 | $110 | $188.5K |
| 81418 | Code 81418 describes a test to evaluate a blood or saliva specimen for changes in at least six genes that may impact metabolism of many therapeutic drugs. The test must include CYP2C19 and CYP2D6… | 150 | $900 | $136.6K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 200 | $70 | $14.9K |
| 81225 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 19, also known as CYP2C19. | 50 | $290 | $12.9K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 70 | $140 | $9.8K |
| 87086 | Culture, bacterial; quantitative, colony count, urine. | 1,190 | $10 | $9.5K |
Showing 1–10 of 48
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 48 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
153 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 627,620 | $60 | $35.1M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 895,940 | $30 | $25.1M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 256,470 | $60 | $14.4M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 216,000 | $50 | $9.7M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 123,970 | $60 | $7.7M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 103,080 | $50 | $4.8M |
| 86481 | The lab analyst performs a test to evaluate an antigen response to certain tuberculosis (TB) antibodies by enumerating T cells that produce gamma interferon. | 31,170 | $50 | $1.5M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 58,350 | $30 | $1.5M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 56,290 | $20 | $1.2M |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 55,700 | $20 | $1.2M |
Showing 1–10 of 153
How this provider's Medicaid billing volume and revenue compare to other Kentucky providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Kentucky median
153 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 70 | 1,650 | $100 | $2M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 50 | 2,830 | $90 | $1.4M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 80 | 990 | $60 | $912.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1 | 340 | 2,700 | $40 | $673.3K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 2 | 30 | 2,090 | $50 | $662.1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 140 | 2,000 | $60 | $639.8K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 39 | 70 | 310 | $100 | $495.2K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 10 | 50 | 570 | $110 | $393.6K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 39 | 200 | 16,730 | $10 | $365.9K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 3 | 80 | 260 | $270 | $358.5K |
Showing 1–10 of 153
Other providers in the same ZIP code as Gravity Diagnostics, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.